U.S., May 2 -- ClinicalTrials.gov registry received information related to the study (NCT06952842) titled 'Safety and Efficacy of ZVS203e in the Treatment of Retinitis Pigmentosa Caused by RHO Gene Mutation' on April 22.
Brief Summary: This trial employs a single-arm, open-label seamless Phase I/II design, consisting of two stages: Phase I dose exploration and Phase II dose expansion.The primary objective of this trial is to evaluate the safety, tolerability, and efficacy of subretinal injection of ZVS203e solution.
Study Start Date: May 18
Study Type: INTERVENTIONAL
Condition:
Retinitis Pigmentosa
Intervention:
DRUG: ZVS203e
ZVS203e injection is a clear, transparent liquid containing a recombinant adeno-associated virus serotype 8 ...